Ellen T. M. Laan
Ellen T. M. Laan has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Cornelis B. Lambalk
Amsterdam UMC Location Vrije Universiteit Amsterdam, IVF Center, Amsterdam, the Netherlands
4 shared publications - Felicia Dreischor
Department of Obstetrics and Gynaecology, Centre for Reproductive Medicine, Amsterdam UMC Location AMC, University of Amsterdam , Amsterdam
4 shared publications - I. M. Custers
Department of Obstetrics and Gynaecology, Centre for Reproductive Medicine, Amsterdam UMC Location AMC, University of Amsterdam , Amsterdam
3 shared publications - Annemieke Hoek
Department of Obstetrics and Gynecology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands
2 shared publications - Birgit I. Lissenberg-Witte
Department of Epidemiology and Data Science, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
2 shared publications - C. Rene Leemans
Amsterdam UMC, Vrije Universiteit Amsterdam, Otolaryngology/Head and Neck Surgery, Cancer Center Amsterdam, The Netherlands
2 shared publications
Latest Publications
- 13 January 2026
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 41 (3) , 361-370
Sexual functioning and its determinants in individuals and their partners with unexplained infertility
STUDY QUESTION: What is the prevalence of sexual dysfunction, and what are the determinants of sexual (dys)functioning in couples with newly diagnosed unexplained infertility? SUMMARY ANSWER: At least one in four couples are at risk of sexual dysfunction, and higher age, longer infertility duration, higher sperm quality, and poorer personal and relational well-being were associated with decreased sexual functioning. WHAT IS KNOWN ALREADY: Many couples diagnosed with unexplained infertility have the ability to conceive naturally over time, but infertility is linked to reduced sexual functioning, which can hinder conception. Surprisingly, sexual functioning, its risk factors, and partner interdependence are still understudied in unexplained infertility, while knowing the risk factors for reduced sexual functioning would enable fertility specialists to timely diagnose, prevent, or treat sexual dysfunction, and in this way improve natural conception rates. STUDY DESIGN, SIZE, DURATION: A cross-sectional survey, which also serves as the baseline assessment of a randomized controlled trial (RCT, 2016–2021). A total of 700 heterosexual couples were addressed. PARTICIPANTS/MATERIALS, SETTING, METHODS: Dutch heterosexual couples (female age 18–38 years) who were able to have coitus and were recently diagnosed with unexplained infertility in secondary or tertiary clinics were eligible. The main outcome measures were sexual functioning as a continuous variable and female and erectile dysfunction based on cut-off scores of the Female Sexual Function Index and International Index of Erectile Function. Determinants included demographic, lifestyle, and diagnostic factors, as well as personal and relational well-being, which were assessed with the Hospital Anxiety and Depression Scale and the Revised Dyadic Adjustment Scale. Sexual (dys)functioning and determinants were subjected to dyadic analysis followed by linear regression. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 581 (83%) women and 478 (68%) men completed the questionnaires. Complete couple data were available for 451 (68.9%) couples. About 1 in 4 women (24.3%) and 1 in 14 men (7.3%) were at risk for, respectively, female sexual dysfunction and erectile dysfunction after a fertility work-up. Couples had a mean coital frequency of seven times per month (SD: 2.7). Higher female and male sexual desire (β: 0.04, P < 0.01 and β: 0.02, P < 0.02) and satisfaction (β: 0.03, P < 0.01 and β: 0.06, P < 0.01), but not orgasm, were significantly associated with increased coital frequency. Lower female sexual functioning (β) or dysfunction (OR) was associated with own age (β: −0.64, OR: 1.12), anxiety (β: −9.47, OR: 4.22), depression (β: −7.61, OR: 3.23), relationship distress (β: −8.97, OR: 2.04), and total motility sperm count (β: −4.88). Lower male sexual functioning was associated with anxiety (β: −5.03), depression (β: −3.65), relationship distress (β: −5.77), and partner's age (β: −0.46) and couple's duration of infertility (β: −0.24, OR: 1.06). LIMITATIONS, REASONS FOR CAUTION: The study is prone to selection bias given the inclusion of couples seeking medical help and consenting to an RCT. Not all previously identified determinants of sexual functioning were studied due to factors such as missing data, low case numbers, or not being assessed in the Pleasure&Pregnancy (P&P) RCT. WIDER IMPLICATIONS OF THE FINDINGS: Clinicians advising couples with unexplained infertility to continue natural conception, given their good prognosis, need to be aware that at least one in four couples are at risk for a sexual dysfunction. Clinicians should consider risk factors of reduced sexual functioning, take a sexual anamnesis, and advise face-to-face or digital (e.g. via website or app) sex counselling and treatment, if indicated. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the Netherlands Organization for Health Research and Development (ZonMW reference: 843001605), University of Amsterdam and Flanders Research Foundation. The funders have no role in considering the design of the study, or collection, analysis, and interpretation of the data, or writing of the report. C.B.L. was the Editor-in-Chief of Human Reproduction until 1 January and has received speakers honorarium and travel support from Merck and Organon. TRIAL REGISTRATION NUMBER: Baseline assessment of the P&P RCT with trial registration number NTR5709.
- 13 January 2026
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 41 (3) , 361-370
Sexual functioning and its determinants in individuals and their partners with unexplained infertility
STUDY QUESTION: What is the prevalence of sexual dysfunction, and what are the determinants of sexual (dys)functioning in couples with newly diagnosed unexplained infertility? SUMMARY ANSWER: At least one in four couples are at risk of sexual dysfunction, and higher age, longer infertility duration, higher sperm quality, and poorer personal and relational well-being were associated with decreased sexual functioning. WHAT IS KNOWN ALREADY: Many couples diagnosed with unexplained infertility have the ability to conceive naturally over time, but infertility is linked to reduced sexual functioning, which can hinder conception. Surprisingly, sexual functioning, its risk factors, and partner interdependence are still understudied in unexplained infertility, while knowing the risk factors for reduced sexual functioning would enable fertility specialists to timely diagnose, prevent, or treat sexual dysfunction, and in this way improve natural conception rates. STUDY DESIGN, SIZE, DURATION: A cross-sectional survey, which also serves as the baseline assessment of a randomized controlled trial (RCT, 2016–2021). A total of 700 heterosexual couples were addressed. PARTICIPANTS/MATERIALS, SETTING, METHODS: Dutch heterosexual couples (female age 18–38 years) who were able to have coitus and were recently diagnosed with unexplained infertility in secondary or tertiary clinics were eligible. The main outcome measures were sexual functioning as a continuous variable and female and erectile dysfunction based on cut-off scores of the Female Sexual Function Index and International Index of Erectile Function. Determinants included demographic, lifestyle, and diagnostic factors, as well as personal and relational well-being, which were assessed with the Hospital Anxiety and Depression Scale and the Revised Dyadic Adjustment Scale. Sexual (dys)functioning and determinants were subjected to dyadic analysis followed by linear regression. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 581 (83%) women and 478 (68%) men completed the questionnaires. Complete couple data were available for 451 (68.9%) couples. About 1 in 4 women (24.3%) and 1 in 14 men (7.3%) were at risk for, respectively, female sexual dysfunction and erectile dysfunction after a fertility work-up. Couples had a mean coital frequency of seven times per month (SD: 2.7). Higher female and male sexual desire (β: 0.04, P < 0.01 and β: 0.02, P < 0.02) and satisfaction (β: 0.03, P < 0.01 and β: 0.06, P < 0.01), but not orgasm, were significantly associated with increased coital frequency. Lower female sexual functioning (β) or dysfunction (OR) was associated with own age (β: −0.64, OR: 1.12), anxiety (β: −9.47, OR: 4.22), depression (β: −7.61, OR: 3.23), relationship distress (β: −8.97, OR: 2.04), and total motility sperm count (β: −4.88). Lower male sexual functioning was associated with anxiety (β: −5.03), depression (β: −3.65), relationship distress (β: −5.77), and partner's age (β: −0.46) and couple's duration of infertility (β: −0.24, OR: 1.06). LIMITATIONS, REASONS FOR CAUTION: The study is prone to selection bias given the inclusion of couples seeking medical help and consenting to an RCT. Not all previously identified determinants of sexual functioning were studied due to factors such as missing data, low case numbers, or not being assessed in the Pleasure&Pregnancy (P&P) RCT. WIDER IMPLICATIONS OF THE FINDINGS: Clinicians advising couples with unexplained infertility to continue natural conception, given their good prognosis, need to be aware that at least one in four couples are at risk for a sexual dysfunction. Clinicians should consider risk factors of reduced sexual functioning, take a sexual anamnesis, and advise face-to-face or digital (e.g. via website or app) sex counselling and treatment, if indicated. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the Netherlands Organization for Health Research and Development (ZonMW reference: 843001605), University of Amsterdam and Flanders Research Foundation. The funders have no role in considering the design of the study, or collection, analysis, and interpretation of the data, or writing of the report. C.B.L. was the Editor-in-Chief of Human Reproduction until 1 January and has received speakers honorarium and travel support from Merck and Organon. TRIAL REGISTRATION NUMBER: Baseline assessment of the P&P RCT with trial registration number NTR5709.
- Open Access
- 7 December 2025
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 23 (1)
Sexual function in women with Polycystic Ovary Syndrome: the role of psychological factors
Background: Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in women of fertile age. It is associated with somatic and psychological comorbidities and lower sexual function. Aim: To study which psychosocial factors predict sexual dysfunction, and dyadic and solitary sexual desire in women with PCOS. Methods: This is an observational case control study amongst healthy heterosexual women with (n = 68) and without PCOS (n = 67), aged 18-40 years, in a steady relationship. All participants filled out questionnaires on sexuality (sexual function, sexual distress, sexual desire), psychosocial factors (general self-esteem, relationship satisfaction, body image, body self-consciousness, sexual esteem, sexual abuse), and mental health (anxiety and depression). Standard multiple regression analyses were performed to assess which factors predict sexual dysfunction and dyadic and solitary sexual desire. Outcomes: sexual dysfunction, dyadic sexual desire, solitary sexual desire. Results: Women with PCOS reported significantly more often sexual dysfunction (41.2% vs. 11.9%, P < .001, φ: 0.331) and lower dyadic sexual desire (P: .005, η: 0.057), but no difference in solitary sexual desire (P: .160, η: 0.015) compared to women without PCOS. Also, women with PCOS reported significantly less positive body image (P: .012, η: 0.047), higher body self-consciousness (P: .011, η: 0.048), higher anxiety (P: .002, η: 0.072), higher depression scores (P: .006, η: 0.055), more sexual abuse experiences (P: .009, φ: 0.225), and less relationship satisfaction (P: .017, η: 0.042). No differences in general self-esteem (P: .169, η: 0.014) were found in contrast to sexual esteem (P: .021, η: 0.039). Body self-consciousness (P: .05, r = 0.242), depression (P: <.001, r = .357), relationship satisfaction (P: .05, r = −0.286), and sexual esteem (P: <.001, r = 0.644) showed significant correlations with sexual dysfunction; and sexual esteem (P: <.001, r = −0.475) and use of the combined oral contraceptive pill (P: .05, r = −0.270) with dyadic sexual desire. Regression showed the strongest associations (all P: <.001) between sexual esteem and sexual dysfunction and dyadic sexual desire, and between depression and sexual dysfunction with moderate explained variance. Clinical Implications: Sexual function should be discussed with women with PCOS and psycho-education on the association with sexual esteem and depression given. Other common psychosocial comorbidities in PCOS should be screened. Refer for psychotherapy or a tailormade psychosexual treatment including interventions targeted on sexual esteem and depression. Strengths and Limitations: Strengths are the broad assessment of psychosocial factors and sexual distress. A weakness is the relatively healthy population possibly underestimating the effect of psychosocial factors. Conclusion: Sexual dysfunction and dyadic sexual desire in women with PCOS are predicted by depression and sexual esteem suggesting psychosexual counseling might be helpful.
- 7 December 2025
- Published by Oxford University Press (OUP) in The Journal of Sexual Medicine
- Vol. 23 (1)
Open AccessSexual function in women with Polycystic Ovary Syndrome: the role of psychological factors
Background: Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in women of fertile age. It is associated with somatic and psychological comorbidities and lower sexual function. Aim: To study which psychosocial factors predict sexual dysfunction, and dyadic and solitary sexual desire in women with PCOS. Methods: This is an observational case control study amongst healthy heterosexual women with (n = 68) and without PCOS (n = 67), aged 18-40 years, in a steady relationship. All participants filled out questionnaires on sexuality (sexual function, sexual distress, sexual desire), psychosocial factors (general self-esteem, relationship satisfaction, body image, body self-consciousness, sexual esteem, sexual abuse), and mental health (anxiety and depression). Standard multiple regression analyses were performed to assess which factors predict sexual dysfunction and dyadic and solitary sexual desire. Outcomes: sexual dysfunction, dyadic sexual desire, solitary sexual desire. Results: Women with PCOS reported significantly more often sexual dysfunction (41.2% vs. 11.9%, P < .001, φ: 0.331) and lower dyadic sexual desire (P: .005, η: 0.057), but no difference in solitary sexual desire (P: .160, η: 0.015) compared to women without PCOS. Also, women with PCOS reported significantly less positive body image (P: .012, η: 0.047), higher body self-consciousness (P: .011, η: 0.048), higher anxiety (P: .002, η: 0.072), higher depression scores (P: .006, η: 0.055), more sexual abuse experiences (P: .009, φ: 0.225), and less relationship satisfaction (P: .017, η: 0.042). No differences in general self-esteem (P: .169, η: 0.014) were found in contrast to sexual esteem (P: .021, η: 0.039). Body self-consciousness (P: .05, r = 0.242), depression (P: <.001, r = .357), relationship satisfaction (P: .05, r = −0.286), and sexual esteem (P: <.001, r = 0.644) showed significant correlations with sexual dysfunction; and sexual esteem (P: <.001, r = −0.475) and use of the combined oral contraceptive pill (P: .05, r = −0.270) with dyadic sexual desire. Regression showed the strongest associations (all P: <.001) between sexual esteem and sexual dysfunction and dyadic sexual desire, and between depression and sexual dysfunction with moderate explained variance. Clinical Implications: Sexual function should be discussed with women with PCOS and psycho-education on the association with sexual esteem and depression given. Other common psychosocial comorbidities in PCOS should be screened. Refer for psychotherapy or a tailormade psychosexual treatment including interventions targeted on sexual esteem and depression. Strengths and Limitations: Strengths are the broad assessment of psychosocial factors and sexual distress. A weakness is the relatively healthy population possibly underestimating the effect of psychosocial factors. Conclusion: Sexual dysfunction and dyadic sexual desire in women with PCOS are predicted by depression and sexual esteem suggesting psychosexual counseling might be helpful.
- Open Access
- 1 October 2024
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 39 (12) , 2711-2721
The web-based Pleasure&Pregnancy programme in the treatment of unexplained infertility: a randomized controlled trial
STUDY QUESTION: Does offering the Pleasure&Pregnancy (P&P) programme rather than expectant management improve naturally conceived ongoing pregnancy rates in couples diagnosed with unexplained infertility? SUMMARY ANSWER: The P&P programme had no effect on the ongoing pregnancy rates of couples with unexplained infertility. WHAT IS KNOWN ALREADY: Underpowered studies suggested that face-to-face interventions targeting sexual health may increase pregnancy rates. The impact of an eHealth sexual health programme had yet to be evaluated by a large randomized controlled trial. STUDY DESIGN, SIZE, DURATION: This is a nationwide multi-centre, unblinded, randomized controlled superiority trial (web-based randomization programme, 1:1 allocation ratio). This RCT intended to recruit 1164 couples within 3 years but was put on hold after having included 700 couples over 5 years (2016–2021). The web-based P&P programme contains psychosexual information and couple communication, mindfulness and sensate focus exercises aiming to help maintain or improve sexual health, mainly pleasure, and hence increase pregnancy rates. The P&P programme additionally offers information on the biology of conception and enables couples to interact online with peers and via email with coaches. PARTICIPANTS/MATERIALS, SETTING, METHODS: Heterosexual couples with unexplained infertility and a Hunault-prognosis of at least 30% chance of naturally conceiving a live-born child within 12 months were included, after their diagnostic work-up in 41 Dutch secondary and tertiary fertility centres. The primary outcome was an ongoing pregnancy, defined as a viable intrauterine pregnancy of at least 12 weeks duration confirmed by an ultrasound scan, conceived naturally within 6 months after randomization. Secondary outcomes were time to pregnancy, live birth, sexual health, and personal and relational well-being at baseline and after 3 and 6 months. The primary analyses were according to intention-to-treat principles. We calculated relative risks (RRs, pregnancy rates) and a risk difference (RD, pregnancy rates), Kaplan–Meier survival curves (live birth over time), and time, group, and interactive effects with mixed models analyses (sexual health and well-being). MAIN RESULTS AND THE ROLE OF CHANCE: Totals of 352 (one withdrawal) and 348 (three withdrawals) couples were allocated to, respectively the P&P group and the expectant management group. Web-based tracking of the intervention group showed a high attrition rate (57% of couples) and limited engagement (i.e. median of 16 visits and 33 min total visitation time per couple). Intention-to-treat analyses showed that 19.4% (n = 68/351) of the P&P group and 22.6% (n = 78/345) of the expectant management group achieved a naturally conceived ongoing pregnancy (RR = 0.86; 95% CI = 0.64–1.15, RD = −3.24%; 95% CI −9.28 to 2.81). The time to pregnancy did not differ between the groups (Log rank = 0.23). Live birth occurred in 18.8% (n = 66/351) of the couples of the P&P group and 22.3% (n = 77/345) of the couples of the expectant management group (RR = 0.84; 95% CI = 0.63–1.1). Intercourse frequency decreased equally over time in both groups. Sexual pleasure, orgasm, and satisfaction of women of the P&P group improved while these outcomes remained stable in the expectant management group. Male orgasm, intercourse satisfaction, and overall satisfaction decreased over time with no differences between groups. The intervention did not affect personal and relational well-being. Non-compliance by prematurely starting medically assisted reproduction, and clinical loss to follow-up were, respectively, 15.1% and 1.4% for the complete study population. Per protocol analysis for the primary outcome did not indicate a difference between the groups. Comparing the most engaged users with the expectant management group added that coital frequency decreased less, and that male sexual desire improved in the intervention group. LIMITATIONS, REASONS FOR CAUTION: The intended sample size of 1164 was not reached because of a slow recruitment rate. The achieved sample size was, however, large enough to exclude an improvement of more than 8% of the P&P programme on our primary outcome. WIDER IMPLICATIONS OF THE FINDINGS: The P&P programme should not be offered to increase natural pregnancy rates but may be considered to improve sexual health. The attrition from and limited engagement with the P&P programme is in line with research on other eHealth programmes and underlines the importance of a user experience study. STUDY FUNDING/COMPETING INTEREST(S): Funded by The Netherlands Organisation for Health Research and Development (ZonMw, reference: 843001605) and Flanders Research Foundation. C.B.L. is editor-in-chief of Human Reproduction. H.W.L. received royalties or licences from Prometheus Publishers Springer Media Thieme Verlag. J.B. received support from MercK for attending the ESHRE course ‘The ESHRE guideline on ovarian stimulation, do we have agreement?’ J.v.D. reports consulting fees and lecture payments from Ferring, not related to the presented work, and support for attending ESHRE from Goodlife and for attending NFI Riga from Merck. A.H. reports consulting fees by Ferring Pharmaceutical company, The Netherlands, paid to institution UMCG, not related to the presented work. H.V. reports consulting fees from Ferring Pharmaceutical company, The Netherlands, and he is a member of the ESHRE guideline development group unexplained infertility and Chair of the Dutch guideline on unexplained infertility (unpaid). M.G. declares unrestricted research and educational grants from Ferring not related to the presented work, paid to their institution VU Medical Centre. The other authors have no conflicts to declare. TRIAL REGISTRATION NUMBER: NTR5709. TRIAL REGISTRATION DATE: 4 February 2016. DATE OF FIRST PATIENT’S ENROLMENT: 27 June 2016.
- 1 October 2024
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 39 (12) , 2711-2721
Open AccessThe web-based Pleasure&Pregnancy programme in the treatment of unexplained infertility: a randomized controlled trial
STUDY QUESTION: Does offering the Pleasure&Pregnancy (P&P) programme rather than expectant management improve naturally conceived ongoing pregnancy rates in couples diagnosed with unexplained infertility? SUMMARY ANSWER: The P&P programme had no effect on the ongoing pregnancy rates of couples with unexplained infertility. WHAT IS KNOWN ALREADY: Underpowered studies suggested that face-to-face interventions targeting sexual health may increase pregnancy rates. The impact of an eHealth sexual health programme had yet to be evaluated by a large randomized controlled trial. STUDY DESIGN, SIZE, DURATION: This is a nationwide multi-centre, unblinded, randomized controlled superiority trial (web-based randomization programme, 1:1 allocation ratio). This RCT intended to recruit 1164 couples within 3 years but was put on hold after having included 700 couples over 5 years (2016–2021). The web-based P&P programme contains psychosexual information and couple communication, mindfulness and sensate focus exercises aiming to help maintain or improve sexual health, mainly pleasure, and hence increase pregnancy rates. The P&P programme additionally offers information on the biology of conception and enables couples to interact online with peers and via email with coaches. PARTICIPANTS/MATERIALS, SETTING, METHODS: Heterosexual couples with unexplained infertility and a Hunault-prognosis of at least 30% chance of naturally conceiving a live-born child within 12 months were included, after their diagnostic work-up in 41 Dutch secondary and tertiary fertility centres. The primary outcome was an ongoing pregnancy, defined as a viable intrauterine pregnancy of at least 12 weeks duration confirmed by an ultrasound scan, conceived naturally within 6 months after randomization. Secondary outcomes were time to pregnancy, live birth, sexual health, and personal and relational well-being at baseline and after 3 and 6 months. The primary analyses were according to intention-to-treat principles. We calculated relative risks (RRs, pregnancy rates) and a risk difference (RD, pregnancy rates), Kaplan–Meier survival curves (live birth over time), and time, group, and interactive effects with mixed models analyses (sexual health and well-being). MAIN RESULTS AND THE ROLE OF CHANCE: Totals of 352 (one withdrawal) and 348 (three withdrawals) couples were allocated to, respectively the P&P group and the expectant management group. Web-based tracking of the intervention group showed a high attrition rate (57% of couples) and limited engagement (i.e. median of 16 visits and 33 min total visitation time per couple). Intention-to-treat analyses showed that 19.4% (n = 68/351) of the P&P group and 22.6% (n = 78/345) of the expectant management group achieved a naturally conceived ongoing pregnancy (RR = 0.86; 95% CI = 0.64–1.15, RD = −3.24%; 95% CI −9.28 to 2.81). The time to pregnancy did not differ between the groups (Log rank = 0.23). Live birth occurred in 18.8% (n = 66/351) of the couples of the P&P group and 22.3% (n = 77/345) of the couples of the expectant management group (RR = 0.84; 95% CI = 0.63–1.1). Intercourse frequency decreased equally over time in both groups. Sexual pleasure, orgasm, and satisfaction of women of the P&P group improved while these outcomes remained stable in the expectant management group. Male orgasm, intercourse satisfaction, and overall satisfaction decreased over time with no differences between groups. The intervention did not affect personal and relational well-being. Non-compliance by prematurely starting medically assisted reproduction, and clinical loss to follow-up were, respectively, 15.1% and 1.4% for the complete study population. Per protocol analysis for the primary outcome did not indicate a difference between the groups. Comparing the most engaged users with the expectant management group added that coital frequency decreased less, and that male sexual desire improved in the intervention group. LIMITATIONS, REASONS FOR CAUTION: The intended sample size of 1164 was not reached because of a slow recruitment rate. The achieved sample size was, however, large enough to exclude an improvement of more than 8% of the P&P programme on our primary outcome. WIDER IMPLICATIONS OF THE FINDINGS: The P&P programme should not be offered to increase natural pregnancy rates but may be considered to improve sexual health. The attrition from and limited engagement with the P&P programme is in line with research on other eHealth programmes and underlines the importance of a user experience study. STUDY FUNDING/COMPETING INTEREST(S): Funded by The Netherlands Organisation for Health Research and Development (ZonMw, reference: 843001605) and Flanders Research Foundation. C.B.L. is editor-in-chief of Human Reproduction. H.W.L. received royalties or licences from Prometheus Publishers Springer Media Thieme Verlag. J.B. received support from MercK for attending the ESHRE course ‘The ESHRE guideline on ovarian stimulation, do we have agreement?’ J.v.D. reports consulting fees and lecture payments from Ferring, not related to the presented work, and support for attending ESHRE from Goodlife and for attending NFI Riga from Merck. A.H. reports consulting fees by Ferring Pharmaceutical company, The Netherlands, paid to institution UMCG, not related to the presented work. H.V. reports consulting fees from Ferring Pharmaceutical company, The Netherlands, and he is a member of the ESHRE guideline development group unexplained infertility and Chair of the Dutch guideline on unexplained infertility (unpaid). M.G. declares unrestricted research and educational grants from Ferring not related to the presented work, paid to their institution VU Medical Centre. The other authors have no conflicts to declare. TRIAL REGISTRATION NUMBER: NTR5709. TRIAL REGISTRATION DATE: 4 February 2016. DATE OF FIRST PATIENT’S ENROLMENT: 27 June 2016.
- Open Access
- 29 September 2023
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (11) , 2230-2238
Sexual dysfunction in women with PCOS: a case control study
What is the relationship of sex steroid levels with sexual function in women with and without polycystic ovary syndrome (PCOS)? Women with PCOS reported more sexual dysfunction and more sexual distress compared to those without PCOS, but only few and weak associations between androgen levels and sexual function were observed. The literature shows that women with PCOS report lower levels of sexual function and sexual satisfactionand more sexual distress. Contributing factors seem to be obesity, alopecia, hirsutism, acne, infertility, anxiety, depression, and low self-esteem. In women with PCOS clinical and/or biochemical hyperandrogenism is common; its relationship with sexualfunction is, however, inconclusive. This observational prospective case control study with 135 women (68 PCOS, 67 control) was conductedfrom March 2017 until March 2020. Heterosexual women with and without PCOS, aged 18–40 years, in a steady relationshipand without any comorbidities, underwent an extensive medical and endocrine screening using liquid chromatography-tandem mass spectrometry and validated sexual function questionnaires. Women with PCOS reported significantly lower sexual function (Female Sexual Function Index (FSFI) P < 0.001, partial η2 = 0.104), higher levels of sexual distress (Female Sexual Distress Scale-Revised P < 0.001, partial η2 = 0.090), and they more often complied with the definition of sexual dysfunction (41.2% vs 11.9%, P < 0.001, Phi V = 0.331) and clinical sexual distress (51.5% vs 19.4%, P < 0.001, Phi V = 0.335). Regression analysis adjusted for confounders showed only few and weak associations between androgen levels and sexual function, with each model explaining a maximum of 15% sexual function. Following significant Group × Hormone interactions, analyses for both groups separately showed no significant associations in the PCOS group. The control group showed only weak negative associations between testosterone and FSFI pain (β = −6.022, P = 0.044, Adj R2 = 0.050), between FAI and FSFI orgasm (β = −3.360, P = 0.023, Adj R2 = 0.049) and between androstenedione and clinical sexual distress (β = −7.293, P = 0.036, exp(β) = 0.001). The focus of the study on sexual functioning potentially creates selection bias. Possibly women with more severe sexual disturbances did or did not choose to participate. Differences between women with PCOS and controls in relationship duration and hormonal contraceptive use might have skewed the sexual function outcomes. Sexual function is impaired in women with PCOS. However, endocrine perturbations seem to have minimal direct impact on sexual function. Addressing sexuality and offering psychosexual counseling is important in the clinical care for women with PCOS. This study was funded by the departments of the participating centers: Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Psychosomatic OBGYN and Sexology, Leiden University Medical Center, Leiden, the Netherlands; and Department of Sexology and Psychosomatic OBGYN, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands. J.S.E.L. received unrestricted research grants from the following companies (in alphabetical order): Ansh Labs, Ferring, Merck Serono and Roche Diagnostics. He also received consultancy fees from Ansh Labs, Ferring, Titus Healthcare and Roche Diagnostics. The other authors have no conflicts of interest. CCMO register, registration number: NL55484.078.16, 10 March 2016. https://www.toetsingonline.nl/to/ccmo_search.nsf/Searchform?OpenForm
- 29 September 2023
- Published by Oxford University Press (OUP) in Human Reproduction
- Vol. 38 (11) , 2230-2238
Open AccessSexual dysfunction in women with PCOS: a case control study
What is the relationship of sex steroid levels with sexual function in women with and without polycystic ovary syndrome (PCOS)? Women with PCOS reported more sexual dysfunction and more sexual distress compared to those without PCOS, but only few and weak associations between androgen levels and sexual function were observed. The literature shows that women with PCOS report lower levels of sexual function and sexual satisfactionand more sexual distress. Contributing factors seem to be obesity, alopecia, hirsutism, acne, infertility, anxiety, depression, and low self-esteem. In women with PCOS clinical and/or biochemical hyperandrogenism is common; its relationship with sexualfunction is, however, inconclusive. This observational prospective case control study with 135 women (68 PCOS, 67 control) was conductedfrom March 2017 until March 2020. Heterosexual women with and without PCOS, aged 18–40 years, in a steady relationshipand without any comorbidities, underwent an extensive medical and endocrine screening using liquid chromatography-tandem mass spectrometry and validated sexual function questionnaires. Women with PCOS reported significantly lower sexual function (Female Sexual Function Index (FSFI) P < 0.001, partial η2 = 0.104), higher levels of sexual distress (Female Sexual Distress Scale-Revised P < 0.001, partial η2 = 0.090), and they more often complied with the definition of sexual dysfunction (41.2% vs 11.9%, P < 0.001, Phi V = 0.331) and clinical sexual distress (51.5% vs 19.4%, P < 0.001, Phi V = 0.335). Regression analysis adjusted for confounders showed only few and weak associations between androgen levels and sexual function, with each model explaining a maximum of 15% sexual function. Following significant Group × Hormone interactions, analyses for both groups separately showed no significant associations in the PCOS group. The control group showed only weak negative associations between testosterone and FSFI pain (β = −6.022, P = 0.044, Adj R2 = 0.050), between FAI and FSFI orgasm (β = −3.360, P = 0.023, Adj R2 = 0.049) and between androstenedione and clinical sexual distress (β = −7.293, P = 0.036, exp(β) = 0.001). The focus of the study on sexual functioning potentially creates selection bias. Possibly women with more severe sexual disturbances did or did not choose to participate. Differences between women with PCOS and controls in relationship duration and hormonal contraceptive use might have skewed the sexual function outcomes. Sexual function is impaired in women with PCOS. However, endocrine perturbations seem to have minimal direct impact on sexual function. Addressing sexuality and offering psychosexual counseling is important in the clinical care for women with PCOS. This study was funded by the departments of the participating centers: Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Psychosomatic OBGYN and Sexology, Leiden University Medical Center, Leiden, the Netherlands; and Department of Sexology and Psychosomatic OBGYN, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands. J.S.E.L. received unrestricted research grants from the following companies (in alphabetical order): Ansh Labs, Ferring, Merck Serono and Roche Diagnostics. He also received consultancy fees from Ansh Labs, Ferring, Titus Healthcare and Roche Diagnostics. The other authors have no conflicts of interest. CCMO register, registration number: NL55484.078.16, 10 March 2016. https://www.toetsingonline.nl/to/ccmo_search.nsf/Searchform?OpenForm
- Open Access
- 12 June 2023
- Published by Taylor & Francis in International Journal of Sexual Health
- Vol. 35 (3) , 313-340
Sexual Pleasure Matters – and How to Define and Assess It Too. A Conceptual Framework of Sexual Pleasure and the Sexual Response
At the beginning of the 21st century, the World Health Organization (WHO, 2002) included pleasure as a component in their definition of sexual health. This definition further championed the sex-pos...
- 12 June 2023
- Published by Taylor & Francis in International Journal of Sexual Health
- Vol. 35 (3) , 313-340
Open AccessSexual Pleasure Matters – and How to Define and Assess It Too. A Conceptual Framework of Sexual Pleasure and the Sexual Response
At the beginning of the 21st century, the World Health Organization (WHO, 2002) included pleasure as a component in their definition of sexual health. This definition further championed the sex-pos...
- Open Access
- 15 November 2022
- Published by Taylor & Francis in The Journal of Sex Research
- Vol. 60 (7) , 969-988
The Sexual Incentive Motivation Model and Its Clinical Applications
Sexual motivation (desire) requires the simultaneous presence of an active central motive state and a stimulus with sexual significance. Once activated, sexual motivation leads to visceral responses and approach behaviors directed toward the emitter of the sexual stimulus. In humans, such behaviors follow cognitive evaluation of the context, including predictions of the approached individual’s response. After successful approach and establishment of physical contact, manifest sexual activities may be initiated. Sexual interaction is associated with and followed by a state of positive affect in most animals, whereas aversive consequences may be experienced by humans. The affective reactions may become associated with stimuli present during sexual interaction, and these stimuli may thereby alter their incentive properties. Here we show how the incentive motivation model can be used to explain the origins and possible treatments of sexual dysfunctions, notably disorders of desire. We propose that associations formed between negative outcomes of sexual interaction and the salient stimuli, for example, the partner, underlies hypoactive desire disorder. Highly positive outcomes of sexual interaction enhance the incentive value of the stimuli present, and eventually lead to hyperactive sexual desire. Treatments aim to alter the impact of sexual incentives, mainly by modifying cognitive processes.
- 15 November 2022
- Published by Taylor & Francis in The Journal of Sex Research
- Vol. 60 (7) , 969-988
Open AccessThe Sexual Incentive Motivation Model and Its Clinical Applications
Sexual motivation (desire) requires the simultaneous presence of an active central motive state and a stimulus with sexual significance. Once activated, sexual motivation leads to visceral responses and approach behaviors directed toward the emitter of the sexual stimulus. In humans, such behaviors follow cognitive evaluation of the context, including predictions of the approached individual’s response. After successful approach and establishment of physical contact, manifest sexual activities may be initiated. Sexual interaction is associated with and followed by a state of positive affect in most animals, whereas aversive consequences may be experienced by humans. The affective reactions may become associated with stimuli present during sexual interaction, and these stimuli may thereby alter their incentive properties. Here we show how the incentive motivation model can be used to explain the origins and possible treatments of sexual dysfunctions, notably disorders of desire. We propose that associations formed between negative outcomes of sexual interaction and the salient stimuli, for example, the partner, underlies hypoactive desire disorder. Highly positive outcomes of sexual interaction enhance the incentive value of the stimuli present, and eventually lead to hyperactive sexual desire. Treatments aim to alter the impact of sexual incentives, mainly by modifying cognitive processes.
- Open Access
- 15 September 2022
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2022 (4) , hoac037
The needs of subfertile couples continuing to attempt natural conception: in-depth interviews
STUDY QUESTION: What are the experiences and the support and sexual advice needs of subfertile couples continuing to attempt natural conception after the diagnostic fertility work-up? SUMMARY ANSWER: Exploration of the experiences of couples showed that couples would have appreciated fertility clinic staff embedding expectant management into the fertility clinic trajectory, supportive staff with female and male patient interactions and advice on common experiences of peers and on managing their lifestyle, distress and subfertility-related sexual challenges. WHAT IS KNOWN ALREADY: Dutch and British professional guidelines advise newly diagnosed subfertile couples with a ‘good prognosis’ to continue to attempt natural conception and do not require fertility clinic staff to interact with patients. Fertility clinic staff and subfertile couples struggle to follow these guidelines as they feel an urgent need for action. Subfertile couples might benefit from sexual advice, as subfertility is negatively associated with sexual functioning, which is important for natural conception. STUDY DESIGN, SIZE, DURATION: Twelve one-time in-depth interviews (2015–2017) were conducted with 10 heterosexual couples and 2 women whose partners did not participate, then the interviews were subjected to inductive content analysis, reaching inductive thematic saturation. PARTICIPANTS/MATERIALS, SETTING, METHODS: The 22 interviewees had experienced 3–18 months of expectant management after their diagnostic fertility work-up in a Belgian or a Dutch tertiary fertility clinic. The face-to-face in-depth interviews explored positive and negative experiences and unmet needs. The transcribed interviews were subjected to inductive content analysis, by two researchers discussing initial disagreements. MAIN RESULTS AND THE ROLE OF CHANCE: Couples would appreciate fertility clinic staff embedding expectant management in the fertility clinic trajectory, by starting off with reassuring couples that their very thorough diagnostic fertility work-up demonstrated their good chance of natural conception, and by involving couples in deciding on the duration of expectant management and by planning the follow-up appointment after expectant management up front. Couples had encountered sexual challenges during expectant management and had an interest in sexual advice, focused on increasing pleasure and partner bonding and preventing the rise of dysfunctions. The couples agreed that a (secured) website with evidence-based, non-patronizing text and mixed media would be an appropriate format for a novel support programme. Couples were keen for interactions with fertility clinic staff which addressed both partners of subfertile couples. Couples also valued advice on managing their lifestyle and distress and would have liked information on the experiences of their peers. LIMITATIONS, REASONS FOR CAUTION: Recall bias is plausible given the retrospective nature of this study. This explorative interview study was not designed for examining country or gender differences in experiences and needs but it did generate new findings on inter-country differences. WIDER IMPLICATIONS OF THE FINDINGS: Rather than simply advising expectant management, fertility clinics are encouraged to offer couples who continue to attempt natural conception after their diagnostic fertility work-up, supportive patient–staff interactions with advice on common experiences of peers and on managing their lifestyle, distress and sexual challenges related to subfertility. STUDY FUNDING/COMPETING INTEREST(S): Funded by Flanders Research Foundation and the University of Amsterdam. There are no competing interests. TRIAL REGISTRATION NUMBER: N/A.
- 15 September 2022
- Published by Oxford University Press (OUP) in Human Reproduction Open
- Vol. 2022 (4) , hoac037
Open AccessThe needs of subfertile couples continuing to attempt natural conception: in-depth interviews
STUDY QUESTION: What are the experiences and the support and sexual advice needs of subfertile couples continuing to attempt natural conception after the diagnostic fertility work-up? SUMMARY ANSWER: Exploration of the experiences of couples showed that couples would have appreciated fertility clinic staff embedding expectant management into the fertility clinic trajectory, supportive staff with female and male patient interactions and advice on common experiences of peers and on managing their lifestyle, distress and subfertility-related sexual challenges. WHAT IS KNOWN ALREADY: Dutch and British professional guidelines advise newly diagnosed subfertile couples with a ‘good prognosis’ to continue to attempt natural conception and do not require fertility clinic staff to interact with patients. Fertility clinic staff and subfertile couples struggle to follow these guidelines as they feel an urgent need for action. Subfertile couples might benefit from sexual advice, as subfertility is negatively associated with sexual functioning, which is important for natural conception. STUDY DESIGN, SIZE, DURATION: Twelve one-time in-depth interviews (2015–2017) were conducted with 10 heterosexual couples and 2 women whose partners did not participate, then the interviews were subjected to inductive content analysis, reaching inductive thematic saturation. PARTICIPANTS/MATERIALS, SETTING, METHODS: The 22 interviewees had experienced 3–18 months of expectant management after their diagnostic fertility work-up in a Belgian or a Dutch tertiary fertility clinic. The face-to-face in-depth interviews explored positive and negative experiences and unmet needs. The transcribed interviews were subjected to inductive content analysis, by two researchers discussing initial disagreements. MAIN RESULTS AND THE ROLE OF CHANCE: Couples would appreciate fertility clinic staff embedding expectant management in the fertility clinic trajectory, by starting off with reassuring couples that their very thorough diagnostic fertility work-up demonstrated their good chance of natural conception, and by involving couples in deciding on the duration of expectant management and by planning the follow-up appointment after expectant management up front. Couples had encountered sexual challenges during expectant management and had an interest in sexual advice, focused on increasing pleasure and partner bonding and preventing the rise of dysfunctions. The couples agreed that a (secured) website with evidence-based, non-patronizing text and mixed media would be an appropriate format for a novel support programme. Couples were keen for interactions with fertility clinic staff which addressed both partners of subfertile couples. Couples also valued advice on managing their lifestyle and distress and would have liked information on the experiences of their peers. LIMITATIONS, REASONS FOR CAUTION: Recall bias is plausible given the retrospective nature of this study. This explorative interview study was not designed for examining country or gender differences in experiences and needs but it did generate new findings on inter-country differences. WIDER IMPLICATIONS OF THE FINDINGS: Rather than simply advising expectant management, fertility clinics are encouraged to offer couples who continue to attempt natural conception after their diagnostic fertility work-up, supportive patient–staff interactions with advice on common experiences of peers and on managing their lifestyle, distress and sexual challenges related to subfertility. STUDY FUNDING/COMPETING INTEREST(S): Funded by Flanders Research Foundation and the University of Amsterdam. There are no competing interests. TRIAL REGISTRATION NUMBER: N/A.
- Open Access
- 31 August 2022
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 37 (10) , 2125-2136
Exploring the impact of urogenital organ displacement after abdominoperineal resection on urinary and sexual function
Purpose: This study aimed to establish the functional impact of displacement of urogenital organs after abdominoperineal resection (APR) using validated questionnaires. Methods: Patients who underwent APR for primary or recurrent rectal cancer (2001–2018) with evaluable pre- and postoperative radiological imaging and completed urinary (UDI-6, IIQ-7) and sexual questionnaires (male, IIEF; female, FSFI, FSDS-R) were included from 16 centers. Absolute displacement of the internal urethral orifice, posterior bladder wall, distal end of the prostatic urethra, and cervix were correlated to urogenital function by calculating Spearman’s Rho (ρ). Median function scores were compared between minimal or substantial displacement using median split. Results: There were 89 male and 36 female patients included, of whom 45 and 19 were sexually active after surgery. Absolute displacement of the internal urethral orifice and posterior bladder wall was not correlated with UDI-6 in men (ρ = 0.119 and ρ = 0.022) nor in women (ρ = − 0.098 and ρ = − 0.154). In men with minimal and substantial displacement of the internal urethral orifice, median UDI-6 scores were 10 (IQR 0–22) and 17 (IQR 5–21), respectively, with corresponding scores of 25 (IQR 10–46) and 21 (IQR 16–36) in women. Displacement of the cervix and FSDS-R were correlated (ρ = 0.433) in sexually active patients. Conclusion: This first analysis on functional impact of urogenital organ displacement after APR suggests that more displacement of the cervix might be associated with worse sexual function, while the data does not indicate any potential functional impact of bladder displacement. Studies are needed to further explore this underexposed topic.
- 31 August 2022
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 37 (10) , 2125-2136
Open AccessExploring the impact of urogenital organ displacement after abdominoperineal resection on urinary and sexual function
Purpose: This study aimed to establish the functional impact of displacement of urogenital organs after abdominoperineal resection (APR) using validated questionnaires. Methods: Patients who underwent APR for primary or recurrent rectal cancer (2001–2018) with evaluable pre- and postoperative radiological imaging and completed urinary (UDI-6, IIQ-7) and sexual questionnaires (male, IIEF; female, FSFI, FSDS-R) were included from 16 centers. Absolute displacement of the internal urethral orifice, posterior bladder wall, distal end of the prostatic urethra, and cervix were correlated to urogenital function by calculating Spearman’s Rho (ρ). Median function scores were compared between minimal or substantial displacement using median split. Results: There were 89 male and 36 female patients included, of whom 45 and 19 were sexually active after surgery. Absolute displacement of the internal urethral orifice and posterior bladder wall was not correlated with UDI-6 in men (ρ = 0.119 and ρ = 0.022) nor in women (ρ = − 0.098 and ρ = − 0.154). In men with minimal and substantial displacement of the internal urethral orifice, median UDI-6 scores were 10 (IQR 0–22) and 17 (IQR 5–21), respectively, with corresponding scores of 25 (IQR 10–46) and 21 (IQR 16–36) in women. Displacement of the cervix and FSDS-R were correlated (ρ = 0.433) in sexually active patients. Conclusion: This first analysis on functional impact of urogenital organ displacement after APR suggests that more displacement of the cervix might be associated with worse sexual function, while the data does not indicate any potential functional impact of bladder displacement. Studies are needed to further explore this underexposed topic.
- Open Access
- 1 April 2022
- Published by Elsevier in Patient Education and Counseling
- Vol. 105 (4) , 858-868
Communication practices in conversations about sexual health in medical healthcare settings: A systematic review
- 1 April 2022
- Published by Elsevier in Patient Education and Counseling
- Vol. 105 (4) , 858-868
Open AccessCommunication practices in conversations about sexual health in medical healthcare settings: A systematic review
- Open Access
- 31 January 2022
- Published by Taylor & Francis in International Journal of Transgender Health
- Vol. 24 (2) , 212-224
Pleasure please! Sexual pleasure and influencing factors in transgender persons: An ENIGI follow-up study
Background: While the importance of sexual pleasure for physical and mental health becomes increasingly evident, research on sexual pleasure in transgender persons is lacking. Recently, the first version of the Amsterdam Sexual Pleasure Index (ASPI Vol. 0.1) was validated in cisgender persons. This questionnaire aims to assess the tendency to experience sexual pleasure independent of gender, sexual orientation or anatomy. Aim: The aims of this study were threefold. First, to perform exploratory scale validation analyses of the ASPI in transgender persons. Secondly, to compare transgender sexual pleasure scores to reference data in cisgender persons. Finally, to identify factors that are associated with sexual pleasure. Methods: In a follow-up study conducted within the European Network for the Investigation of Gender Incongruence (ENIGI), online questionnaires were distributed to persons who had a first clinical contact at gender clinics in Amsterdam, Ghent or Hamburg four to six years earlier. Internal consistency of the ASPI was assessed by calculating McDonald’s omega (ωt). ASPI scores were compared to scores from the cisgender population using a one sample t-test, and linear regressions were conducted to study associations with clinical characteristics, psychological wellbeing, body satisfaction and self-reported happiness. Results: In total, 325 persons filled out the ASPI. The ASPI showed excellent internal consistency (ωt, all: 0.97; transfeminine: 0.97, transmasculine: 0.97). Compared to data from cisgender persons, transgender participants had significantly lower total ASPI scores (i.e., lower sexual pleasure; transgender vs. cisgender, mean(SD): 4.13(0.94) vs. 4.71(0.61)). Lower age, current happiness and genital body satisfaction were associated with a higher tendency to experience sexual pleasure. Conclusion & discussion: The ASPI can be used to assess the tendency to experience sexual pleasure and associated factors in transgender persons. Future studies are needed to understand interplaying biopsychosocial factors that promote sexual pleasure and hence transgender sexual health and wellbeing.
- 31 January 2022
- Published by Taylor & Francis in International Journal of Transgender Health
- Vol. 24 (2) , 212-224
Open AccessPleasure please! Sexual pleasure and influencing factors in transgender persons: An ENIGI follow-up study
Background: While the importance of sexual pleasure for physical and mental health becomes increasingly evident, research on sexual pleasure in transgender persons is lacking. Recently, the first version of the Amsterdam Sexual Pleasure Index (ASPI Vol. 0.1) was validated in cisgender persons. This questionnaire aims to assess the tendency to experience sexual pleasure independent of gender, sexual orientation or anatomy. Aim: The aims of this study were threefold. First, to perform exploratory scale validation analyses of the ASPI in transgender persons. Secondly, to compare transgender sexual pleasure scores to reference data in cisgender persons. Finally, to identify factors that are associated with sexual pleasure. Methods: In a follow-up study conducted within the European Network for the Investigation of Gender Incongruence (ENIGI), online questionnaires were distributed to persons who had a first clinical contact at gender clinics in Amsterdam, Ghent or Hamburg four to six years earlier. Internal consistency of the ASPI was assessed by calculating McDonald’s omega (ωt). ASPI scores were compared to scores from the cisgender population using a one sample t-test, and linear regressions were conducted to study associations with clinical characteristics, psychological wellbeing, body satisfaction and self-reported happiness. Results: In total, 325 persons filled out the ASPI. The ASPI showed excellent internal consistency (ωt, all: 0.97; transfeminine: 0.97, transmasculine: 0.97). Compared to data from cisgender persons, transgender participants had significantly lower total ASPI scores (i.e., lower sexual pleasure; transgender vs. cisgender, mean(SD): 4.13(0.94) vs. 4.71(0.61)). Lower age, current happiness and genital body satisfaction were associated with a higher tendency to experience sexual pleasure. Conclusion & discussion: The ASPI can be used to assess the tendency to experience sexual pleasure and associated factors in transgender persons. Future studies are needed to understand interplaying biopsychosocial factors that promote sexual pleasure and hence transgender sexual health and wellbeing.